New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

intermed medical ltd - alanine 4.22 mg/ml; arginine 4.32 mg/ml; aspartic acid 2.98 mg/ml; calcium 0.005 meq/ml (electrolytes); chlorine 0.048 meq/ml (electrolytes); glucose 20%; glutamic acid 3.14 mg/ml; glycine 2.12 mg/ml; histidine 1.28 mg/ml; isoleucine 2.8 mg/ml; leucine 4.25 mg/ml; lysine 4.46 mg/ml (as lysine acetate. includes 0.0306meq/ml acetate ions); magnesium 0.005 meq/ml (electrolytes); methionine 0.73 mg/ml; phenylalanine 1.26 mg/ml; phosphorus 0.015 mmol/ml (electrolytes); potassium 0.033 meq/ml (electrolytes); proline 2.52 mg/ml; serine 2.25 mg/ml; sodium 0.04 meq/ml (electrolytes); threonine 1.7 mg/ml; tryptophan 0.85 mg/ml; tyrosine 1.15 mg/ml; valine 2.12 mg/ml - solution for infusion - 4.25 % - active: alanine 4.22 mg/ml arginine 4.32 mg/ml aspartic acid 2.98 mg/ml calcium 0.005 meq/ml (electrolytes) chlorine 0.048 meq/ml (electrolytes) glucose 20% glutamic acid 3.14 mg/ml glycine 2.12 mg/ml histidine 1.28 mg/ml isoleucine 2.8 mg/ml leucine 4.25 mg/ml lysine 4.46 mg/ml (as lysine acetate. includes 0.0306meq/ml acetate ions) magnesium 0.005 meq/ml (electrolytes) methionine 0.73 mg/ml phenylalanine 1.26 mg/ml phosphorus 0.015 mmol/ml (electrolytes) potassium 0.033 meq/ml (electrolytes) proline 2.52 mg/ml serine 2.25 mg/ml sodium 0.04 meq/ml (electrolytes) threonine 1.7 mg/ml tryptophan 0.85 mg/ml tyrosine 1.15 mg/ml valine 2.12 mg/ml

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

intermed medical ltd - alanine 4.22 mg/ml; arginine 4.32 mg/ml; aspartic acid 2.98 mg/ml; calcium 0.0306 meq/ml (electrolytes); chlorine 0.048 meq/ml (electrolytes); glucose 25%; glutamic acid 3.14 mg/ml; glycine 2.12 mg/ml; histidine 1.28 mg/ml; isoleucine 2.8 mg/ml; leucine 4.25 mg/ml; lysine 4.46 mg/ml (as lysine acetate. includes 0.0252meq/ml acetate ions); magnesium 0.005 meq/ml (electrolytes); methionine 0.73 mg/ml; phenylalanine 1.26 mg/ml; phosphorus 0.015 mmol/ml (electrolytes); potassium 0.033 meq/ml (electrolytes); proline 3.07 mg/ml; serine 2.25 mg/ml; sodium 0.04 meq/ml (electrolytes); threonine 1.7 mg/ml; tryptophan 0.85 mg/ml; tyrosine 1.15 mg/ml; valine 2.12 mg/ml - solution for infusion - 4.25 % - active: alanine 4.22 mg/ml arginine 4.32 mg/ml aspartic acid 2.98 mg/ml calcium 0.0306 meq/ml (electrolytes) chlorine 0.048 meq/ml (electrolytes) glucose 25% glutamic acid 3.14 mg/ml glycine 2.12 mg/ml histidine 1.28 mg/ml isoleucine 2.8 mg/ml leucine 4.25 mg/ml lysine 4.46 mg/ml (as lysine acetate. includes 0.0252meq/ml acetate ions) magnesium 0.005 meq/ml (electrolytes) methionine 0.73 mg/ml phenylalanine 1.26 mg/ml phosphorus 0.015 mmol/ml (electrolytes) potassium 0.033 meq/ml (electrolytes) proline 3.07 mg/ml serine 2.25 mg/ml sodium 0.04 meq/ml (electrolytes) threonine 1.7 mg/ml tryptophan 0.85 mg/ml tyrosine 1.15 mg/ml valine 2.12 mg/ml

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

intermed medical ltd - alanine 6.98 mg/ml; arginine 12.27 mg/ml; aspartic acid 5.27 mg/ml; glutamic acid 8.2 mg/ml; glycine 3.85 mg/ml; histidine 3.12 mg/ml; isoleucine 7.6 mg/ml; leucine 12 mg/ml; lysine 6.77 mg/ml; methionine 1.8 mg/ml; phenylalanine 4.27 mg/ml; proline 8.12 mg/ml; serine 4.95 mg/ml; taurine 0.7 mg/ml; threonine 5.12 mg/ml; tryptophan 1.8 mg/ml; tyrosine 0.44 mg/ml; valine 6.73 mg/ml - solution for infusion - 10 % - active: alanine 6.98 mg/ml arginine 12.27 mg/ml aspartic acid 5.27 mg/ml glutamic acid 8.2 mg/ml glycine 3.85 mg/ml histidine 3.12 mg/ml isoleucine 7.6 mg/ml leucine 12 mg/ml lysine 6.77 mg/ml methionine 1.8 mg/ml phenylalanine 4.27 mg/ml proline 8.12 mg/ml serine 4.95 mg/ml taurine 0.7 mg/ml threonine 5.12 mg/ml tryptophan 1.8 mg/ml tyrosine 0.44 mg/ml valine 6.73 mg/ml

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

intermed medical ltd - alanine 4.9 mg/ml; arginine 8.61 mg/ml; aspartic acid 3.7 mg/ml; glutamic acid 5.76 mg/ml; glycine 2.7 mg/ml; histidine 2.2 mg/ml; isoleucine 5.34 mg/ml; leucine 8.31 mg/ml; lysine 4.75 mg/ml; methionine 1.25 mg/ml; phenylalanine 3 mg/ml; proline 5.7 mg/ml; serine 3.47 mg/ml; taurine 0.5 mg/ml; threonine 3.6 mg/ml; tryptophan 1.25 mg/ml; tyrosine 0.44 mg/ml; valine 4.52 mg/ml - solution for infusion - 7 % - active: alanine 4.9 mg/ml arginine 8.61 mg/ml aspartic acid 3.7 mg/ml glutamic acid 5.76 mg/ml glycine 2.7 mg/ml histidine 2.2 mg/ml isoleucine 5.34 mg/ml leucine 8.31 mg/ml lysine 4.75 mg/ml methionine 1.25 mg/ml phenylalanine 3 mg/ml proline 5.7 mg/ml serine 3.47 mg/ml taurine 0.5 mg/ml threonine 3.6 mg/ml tryptophan 1.25 mg/ml tyrosine 0.44 mg/ml valine 4.52 mg/ml

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - alanine 7.28 mg/ml;  ; arginine 3.64 mg/ml;  ; dibasic potassium phosphate 1.31 mg/ml; glycine 7.28 mg/ml;  ; histidine 1.54 mg/ml;  ; isoleucine 1.68 mg/ml;  ; leucine 2.17 mg/ml;  ; lysine 2.03 mg/ml;  ; magnesium chloride hexahydrate 0.51 mg/ml; methionine 2.03 mg/ml;  ; phenylalanine 2.17 mg/ml;  ; proline 1.47 mg/ml;  ; sodium acetate trihydrate 2.18 mg/ml; sodium chloride 0.3 mg/ml; threonine 1.47 mg/ml;  ; tryptophan 0.63 mg/ml;  ; tyrosine 0.14 mg/ml;  ; valine 1.61 mg/ml;   - solution for infusion - 3.5 % - active: alanine 7.28 mg/ml   arginine 3.64 mg/ml   dibasic potassium phosphate 1.31 mg/ml glycine 7.28 mg/ml   histidine 1.54 mg/ml   isoleucine 1.68 mg/ml   leucine 2.17 mg/ml   lysine 2.03 mg/ml   magnesium chloride hexahydrate 0.51 mg/ml methionine 2.03 mg/ml   phenylalanine 2.17 mg/ml   proline 1.47 mg/ml   sodium acetate trihydrate 2.18 mg/ml sodium chloride 0.3 mg/ml threonine 1.47 mg/ml   tryptophan 0.63 mg/ml   tyrosine 0.14 mg/ml   valine 1.61 mg/ml   excipient: acetic acid sodium bisulfite water for injection

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

biomed limited - alanine 3.2 mg/ml; arginine 7.3 mg/ml; aspartic acid 1.9 mg/ml; cysteine 0.2 mg/ml; glutamic acid 3 mg/ml; glycine 2.2 mg/ml; histidine 2.9 mg/ml; isoleucine 4.9 mg/ml; leucine 8.4 mg/ml; lysine 4.9 mg/ml; methionine 2 mg/ml; phenylalanine 2.9 mg/ml; proline 4.1 mg/ml; serine 2.3 mg/ml; taurine 0.15 mg/ml; threonine 2.5 mg/ml; tryptophan 1.2 mg/ml; tyrosine 1.4 mg/ml; valine 4.7 mg/ml - solution for infusion - 6 % - active: alanine 3.2 mg/ml arginine 7.3 mg/ml aspartic acid 1.9 mg/ml cysteine 0.2 mg/ml glutamic acid 3 mg/ml glycine 2.2 mg/ml histidine 2.9 mg/ml isoleucine 4.9 mg/ml leucine 8.4 mg/ml lysine 4.9 mg/ml methionine 2 mg/ml phenylalanine 2.9 mg/ml proline 4.1 mg/ml serine 2.3 mg/ml taurine 0.15 mg/ml threonine 2.5 mg/ml tryptophan 1.2 mg/ml tyrosine 1.4 mg/ml valine 4.7 mg/ml excipient: glacial acetic acid sodium metabisulfite water for injection

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - methylphenidate hydrochloride 54mg (drug layer 1, drug layer 2 & drug coat);   - modified release tablet - 54 mg - active: methylphenidate hydrochloride 54mg (drug layer 1, drug layer 2 & drug coat)   excipient: butylated hydroxytoluene carnauba wax cellulose acetate hypromellose ferric oxide, green (push layer) iron oxide red opacode black ns-78-17715 opadry clear ys-1-19025-a opadry red y-30-15567-a phosphoric acid poloxamer 188 polyethylene oxide povidone sodium chloride stearic acid succinic acid - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. need for comprehensive treatment programme: concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms. long term use: the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml;  ; potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage);  ;   - powder for oral suspension - 250mg, 62.5mg/5ml - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml   potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - reboxetine mesilate 5.224mg equivalent to 4 mg reboxetine free base - tablet - 4 mg - active: reboxetine mesilate 5.224mg equivalent to 4 mg reboxetine free base excipient: calcium hydrogen phosphate dihydrate crospovidone hydrated silica magnesium stearate powdered cellulose

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - metronidazole benzoate 64 mg/ml equivalent to 40 mg/ml metronidazole.;  ;   - oral suspension - 200 mg/5ml - active: metronidazole benzoate 64 mg/ml equivalent to 40 mg/ml metronidazole.     excipient: aluminium magnesium silicate citrus limon ethanol methyl hydroxybenzoate monobasic sodium phosphate dihydrate propyl hydroxybenzoate purified water sucrose liquid terpeneless orange oil